



NASDAQ: GNPX

## CORPORATE FACT SHEET

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.

Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

### GENERAL COMPANY INFORMATION

- Founded in 2009: Publicly traded company (NASDAQ: GNPX) since 2018
- Headquartered in Austin, Texas
- Strong balance sheet that well positions Genprex to advance its programs

### COMPETITIVE ADVANTAGES

- Addressing unmet medical need in large markets through the buildout of a robust pipeline of new drug candidates and drug combinations.
- Leveraging a gene therapy platform; Genprex’s non-viral ONCOPREX® Nanoparticle Delivery System is designed to deliver a variety of therapeutic genes to fight multiple types of cancer.
- REQORSA™ immunogene therapy, the first systemically delivered gene therapy used for cancer in humans, can be combined with top-selling cancer drugs and may improve their benefits.
- Genprex has demonstrated clinical achievement with REQORSA in two clinical trials, showing a favorable safety profile and evidence of efficacy in lung cancer.
- GPX-002, Genprex’s diabetes gene therapy, works to transform alpha cells in the pancreas into insulin producing beta-like cells. A Phase 1 clinical trial could be the first-ever gene therapy tested in humans for diabetes.

### Acclaim .1

- Phase 1/2 study of REQORSA in combination with AstraZeneca’s Tagrisso® for NSCLC
- Late-stage, EGFR mutant NSCLC patients whose disease progressed after Tagrisso
- Fast Track Designation

### Acclaim .2

- Phase 1/2 study of REQORSA in combination with Merck & Co’s Keytruda® for NSCLC
- Late-stage NSCLC patients whose disease progressed after responding to Keytruda
- Fast Track Designation

Statements contained herein not historical in nature are “forward-looking statements” (FLS) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such FLS and include statements relating to effects of our product candidates, planned clinical trials and potential partnerships, all as more fully described in Genprex’s SEC filings.

To learn more about us, please visit:

[GENPREX.COM](http://GENPREX.COM)

# REPROGRAMMING THE COURSE OF CANCER AND DIABETES